Among 2 analysts covering Capital Regional PLC (LON:CAL), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Capital Regional PLC had 13 analyst reports since March 5, 2019 according to SRatingsIntel. Berenberg maintained the shares of CAL in report on Monday, March 18 with “Buy” rating. JP Morgan maintained it with “Neutral” rating and GBX 28 target in Wednesday, April 10 report. Peel Hunt upgraded Capital & Regional Plc (LON:CAL) rating on Monday, June 17. Peel Hunt has “Hold” rating and GBX 16 target. See Capital & Regional Plc (LON:CAL) latest ratings:

09/07/2019 Broker: Peel Hunt Rating: Hold Old Target: GBX 16.00 Maintain
25/06/2019 Broker: Peel Hunt Rating: Hold Old Target: GBX 16.00 Maintain
17/06/2019 Broker: Peel Hunt Rating: Hold Old Target: GBX 28.00 New Target: GBX 16.00 Upgrade
11/06/2019 Broker: Peel Hunt Rating: Reduce Old Target: GBX 28.00 Maintain
04/06/2019 Broker: Peel Hunt Rating: Reduce Old Target: GBX 28.00 Maintain
28/05/2019 Broker: Peel Hunt Rating: Reduce Old Target: GBX 28.00 Maintain
17/05/2019 Broker: Peel Hunt Rating: Reduce Old Target: GBX 28.00 Maintain
14/05/2019 Broker: Peel Hunt Rating: Reduce Old Target: GBX 28.00 Maintain
08/05/2019 Broker: Peel Hunt Rating: Reduce Old Target: GBX 28.00 Maintain
10/04/2019 Broker: JP Morgan Rating: Neutral Old Target: GBX 32.00 New Target: GBX 28.00 Maintain

Analysts expect KemPharm, Inc. (NASDAQ:KMPH) to report $-0.44 EPS on August, 8.They anticipate $0.47 EPS change or 51.65% from last quarter’s $-0.91 EPS. After having $-0.46 EPS previously, KemPharm, Inc.’s analysts see -4.35% EPS growth. The stock increased 0.72% or $0.01 during the last trading session, reaching $1.39. About 450,876 shares traded or 218.19% up from the average. KemPharm, Inc. (NASDAQ:KMPH) has declined 78.31% since July 25, 2018 and is downtrending. It has underperformed by 82.74% the S&P500. Some Historical KMPH News: 29/03/2018 - KemPharm 4Q Loss/Shr 72c; 29/03/2018 - KEMPHARM INC - PLANS TO CONTINUE ITS ATM OFFERING TO PROVIDE A PORTION OF CAPITAL NEEDED TO FUND ONGOING OPERATIONS; 10/05/2018 - KEMPHARM INC - KP415 PRODRUG DEMONSTRATED STATISTICALLY SIGNIFICANT DIFFERENCES COMPARED TO D-METHYLPHENIDATE HYDROCHLORIDE IN PRIMARY ENDPOINT; 29/03/2018 KemPharm Reports 4Q and Yr End 2017 Results; 10/05/2018 - KemPharm 1Q Loss $26.2M; 10/05/2018 - KemPharm 1Q Loss/Shr $1.77; 29/03/2018 - KemPharm: Cash, Security-Related Amounts $48.6M at Dec. 3; 29/03/2018 - KemPharm: Resources Not Expected to Be Sufficient to Fund Operating Expenses Through 1Q 2019; 20/04/2018 - DJ KemPharm Inc, Inst Holders, 1Q 2018 (KMPH); 10/05/2018 - KEMPHARM INC - NO STATISTICALLY SIGNIFICANT DIFFERENCE IN MEAN DRUG LIKING E(MAX) BETWEEN KP415 PRODRUG (57 POINTS) AND PLACEBO (54 POINTS)

More notable recent KemPharm, Inc. (NASDAQ:KMPH) news were published by: Finance.Yahoo.com which released: “Could The KemPharm, Inc. (NASDAQ:KMPH) Ownership Structure Tell Us Something Useful? - Yahoo Finance” on July 05, 2019, also Benzinga.com with their article: “Hyperloop Test Pod Breaks Speed Record And Wins The Annual Hyperloop Pod Competition - Benzinga” published on July 24, 2019, Globenewswire.com published: “KemPharm Reports First Quarter 2019 Results Nasdaq:KMPH - GlobeNewswire” on May 14, 2019. More interesting news about KemPharm, Inc. (NASDAQ:KMPH) were released by: Globenewswire.com and their article: “KemPharm Reports Q4 and FY 2018 Results Nasdaq:KMPH - GlobeNewswire” published on February 28, 2019 as well as Globenewswire.com‘s news article titled: “KemPharm to Present at Upcoming Investor Conferences - GlobeNewswire” with publication date: March 05, 2019.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. The company has market cap of $39.64 million. The Company’s lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. It currently has negative earnings. The firm is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders.

Capital & Regional plc operates as a co-investing property asset management firm in the United Kingdom and Germany. The company has market cap of 120.15 million GBP. It primarily focuses on retail and leisure sectors. It currently has negative earnings. The firm manages property assets for funds and joint ventures in which it holds stake.

More notable recent Capital & Regional Plc (LON:CAL) news were published by: Finance.Yahoo.com which released: “Some Capital & Regional (LON:CAL) Shareholders Have Copped A Big 63% Share Price Drop - Yahoo Finance” on April 25, 2019, also Finance.Yahoo.com with their article: “Caleres, Inc. (NYSE:CAL) Is Yielding 1.4% - But Is It A Buy? - Yahoo Finance” published on June 13, 2019, Finance.Yahoo.com published: “Caleres Inc. (CAL) Meets Q1 Earnings Estimates - Yahoo Finance” on June 03, 2019. More interesting news about Capital & Regional Plc (LON:CAL) were released by: Finance.Yahoo.com and their article: “Did Changing Sentiment Drive Caleres’s (NYSE:CAL) Share Price Down By 20%? - Yahoo Finance” published on May 07, 2019 as well as Finance.Yahoo.com‘s news article titled: “Ashford Hospitality Trust: 1Q Earnings Snapshot - Yahoo Finance” with publication date: May 03, 2019.

The stock increased 2.48% or GBX 0.4 during the last trading session, reaching GBX 16.54. About 1.28M shares traded. Capital & Regional Plc (LON:CAL) has 0.00% since July 25, 2018 and is . It has underperformed by 4.43% the S&P500. Some Historical CAL News: 12/03/2018 - Sam Edelman Debuts its Spring/Summer 2018 Campaign, Featuring Model Carolyn Murphy; 10/05/2018 - Caleres Names Molly Adams Pres of Famous Footwear; 06/03/2018 Caleres Closes Above 200-Day Moving Average: Technicals; 13/03/2018 - CALERES INC SEES 2018 BRAND PORTFOLIO SALES UP LOW-SINGLE DIGITS; 13/03/2018 - CALERES 4Q EPS 47C; 20/04/2018 - DJ Caleres Inc, Inst Holders, 1Q 2018 (CAL); 14/03/2018 - Caleres Closes Above 50-Day Moving Average: Technicals; 13/03/2018 - Caleres Profit, Revenue Rise in Latest Quarter; 13/03/2018 - Caleres Sees 2018 Adj EPS $2.40-Adj EPS $2.50; 08/03/2018 - Caleres Regular Quarterly Dividend